Swedish Orphan Biovitrum AB Q2 2025 Report Highlights

Swedish Orphan Biovitrum AB has published its Q2 2025 report, detailing the company’s financial performance for the period.

  • Total revenue increased by 13% and 22% at constant exchange rates compared to the same period in the previous year.
  • The revenue growth was driven by the launch of Altuvoct and growth in haematology revenue.

Share Repurchase Authorization

The Board of Directors has exercised its authorization to repurchase shares to secure commitments under incentive programs.

Outlook and Earnings Per Share

The company’s outlook for the year remains unchanged, with analysts predicting a significant increase in earnings per share.

CEO’s Comments

The CEO has expressed optimism about the company’s prospects, citing the potential for NASP to become one of the company’s top-selling products.

Key Statistics

  • Revenue growth at constant exchange rates: 13% and 22%
  • Revenue drivers: launch of Altuvoct and growth in haematology revenue
  • Outlook for the year: unchanged
  • Analysts’ prediction: significant increase in earnings per share